Pacific Biosciences of California Inc PACB.OQ PACB.O is expected to show a rise in quarterly revenue when it reports results on April 7 (estimated) for the period ending March 31 2026
The Menlo Park California-based company is expected to report a 7.6% increase in revenue to $39.986 million from $37.15 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Pacific Biosciences of California Inc is for a loss of 13 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 1.0% in the last three months.
Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.50, about 86.6% above its last closing price of $1.34
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2025 | -0.12 | -0.15 | -0.12 | Beat | 18.6 |
Sep. 30 2025 | -0.12 | -0.15 | -0.13 | Beat | 14.5 |
Jun. 30 2025 | -0.17 | -0.17 | -0.14 | Beat | 17.6 |
Mar. 31 2025 | -0.19 | -0.19 | -1.44 | Missed | -661.9 |
Dec. 31 2024 | -0.21 | -0.21 | -0.49 | Missed | -138.6 |
Sep. 30 2024 | -0.24 | -0.22 | -0.22 | Met | 2 |
Jun. 30 2024 | -0.24 | -0.23 | -0.64 | Missed | -175.1 |
Mar. 31 2024 | -0.28 | -0.28 | -0.29 | Missed | -5.3 |
This summary was machine generated April 3 at 11:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments